Nanopublication

< Home

ID

http://purl.org/np/RA0FHkROmDX11eRGOg2zWiFGhL_kXfzSKr9iuXZOzZ1Os

Formats

.trig | .trig.txt | .jelly | .jelly.txt | .jsonld | .jsonld.txt | .nq | .nq.txt | .xml | .xml.txt

Content

@prefix orcid: <https://orcid.org/> .
@prefix this: <http://purl.org/np/RA0FHkROmDX11eRGOg2zWiFGhL_kXfzSKr9iuXZOzZ1Os> .
@prefix sub: <http://purl.org/np/RA0FHkROmDX11eRGOg2zWiFGhL_kXfzSKr9iuXZOzZ1Os#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix ns2: <http://twoc-nlp-database-server-1:8555/solr/triples/select?q=> .
@prefix ns1: <https://uts.nlm.nih.gov/uts/umls/concept/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix ns3: <http://twoc-nlp-database-server-1:8555/solr/predicates/select?q=> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo .
}

sub:assertion {
  sub:assertion prov:wasGeneratedBy "S&T TWOC project version 1" .
  
  sub:version prov:value "1"^^xsd:integer .
  
  rdf:object ns1:C0442886 "secondary infections" .
  
  rdf:predicate ns3:TRIPLE_UID:kmvq6bit-TRIPLE-ABSTRACT-9 "experience" .
  
  rdf:subject ns1:C0011777 "dexamethasone";
    ns1:C0030705 "patients";
    ns1:C0441833 "group";
    ns1:C0687744 "group";
    ns1:C1257890 "group";
    ns1:C1442989 "standard";
    ns1:C1548173 "standard";
    ns1:C1561557 "group";
    ns1:C1705428 "group";
    ns1:C1705429 "group";
    ns1:C1947933 "care";
    ns1:C2362566 "care";
    ns1:C2828392 "standard";
    ns1:C3272550 "standard" .
  
  rdfs:Triple-UID ns2:TRIPLE_UID:kmvq6bit-TRIPLE-ABSTRACT-9 "kmvq6bit-TRIPLE-ABSTRACT-9" .
  
  rdfs:sentence rdfs:label "Thirty-three patients (21.9%) in the dexamethasone group vs 43 (29.1%) in the standard care group experienced secondary infections, 47 (31.1%) vs 42 (28.3%) needed insulin for glucose control, and 5 (3.3%) vs 9 (6.1%) experienced other serious adverse events." .
  
  rdfs:triple rdfs:label "Thirty - three patients ( 21.9 % ) in the dexamethasone group vs 43 ( 29.1 % ) in the standard care group experienced secondary infections" .
}

sub:provenance {
  sub:assertion prov:generatedAtTime "2021-07-25T21:45:49.773306"^^xsd:dateTime .
}

sub:pubInfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB";
    npx:hasSignature "RnTbRncETO8rcPKb0HBPakUVuL0neiEyHGUfEMJ2fykJhGvgukg7SaLYPwNHr3ConoWrBe5EB0wnwNIUY3+KZnVW08+HZdMQT4z48kt1g7KgCezstbdeIyPKN81e+gjPkyWJiKVd3OE0asrdZkUoSILfJHaK1ZQwner7tWg7/ZY=";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2021-07-25T21:45:49.773306"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-8954-0470 .
}